Torrey Pines Investment

Mair Pharmaceutical creates innovative processes and produces well-known unique substances for pharmaceutical and biopharmaceutical firms worldwide.

Mair Therapeutics is a biotechnology company focused on developing treatments for neurodegenerative disorders, with a particular emphasis on Parkinson's disease. The company's platform specializes in discovering small-molecule ion channel activators that regulate the lysosomal ion channel TMEM175, controlling lysosomal pH to degrade protein aggregates associated with these conditions. Currently, Mair Therapeutics is in the preclinical drug discovery phase.

BIMINI Biotech is a pre-clinical medical startup based in Leiden, The Netherlands, founded in 2019. The company focuses on developing innovative therapeutic strategies for oncology, specifically targeting the growth hormone receptor (GHR) and its interaction with insulin-like growth factor 1 (IGF-1). By rendering the growth hormone receptor dysfunctional, BIMINI Biotech aims to reduce cellular sensitivity to growth hormone, a mechanism observed in Laron syndrome. This approach holds potential for the treatment of cancer, metabolic diseases, and aging, positioning the company as a significant player in the advancement of anti-cancer therapies.

Lomond Therapeutics is a pharmaceutical company specializing in the discovery and development of small molecule inhibitors targeting escape variants in hematologic malignancies.

Polku Therapeutics is a therapeutics company specializing in the development of novel treatments for neurodegenerative disorders. It employs a virtual drug development model, combining cost efficiency and adaptability, to collaborate with experts globally and offer new treatment options for conditions such as Parkinson's disease and Alzheimer's.

i2020 Accelerator, founded in 2017 and based in San Diego, California, is an organization dedicated to supporting early-stage drug discovery companies. It specializes in providing funding and resources to firms focused on areas such as inflammation, oncology, central nervous system disorders, and infectious diseases. By targeting companies that are advancing their lead and clinical candidate levels, i2020 Accelerator aims to facilitate the development of innovative therapeutics and contribute to advancements in healthcare. Through its accelerator model, it offers not only financial support but also strategic guidance to help these companies progress in their research and development efforts.

Context Therapeutics is a clinical-stage biopharmaceutical company based in Philadelphia focused on developing medicines for hormone-responsive cancers, especially female, hormone-dependent tumors such as breast, ovarian, and endometrial cancers. Its lead program Apristor (Onapristone XR) is an investigational Phase 2 therapy for progesterone receptor–positive metastatic breast and ovarian cancers. The company is advancing CTX-030916, an oral antiprogestin candidate for uterine fibroids and endometriosis, and pursuing a discovery-stage program targeting Sigma1. It also has a preclinical program, CTIM-76, developing an anti-CLDN6 × anti-CD3 bispecific antibody to redirect T-cell–mediated killing toward Claudin 6–expressing cancer cells. Context Therapeutics aims to address hormone-driven solid tumors with a portfolio spanning clinical and preclinical assets.

Viriom Inc. is a biotechnology company based in Khimki, Russia, established in 2009. It specializes in developing innovative and affordable medicines for life-threatening infections, particularly HIV and Hepatitis B virus (HBV). Viriom holds an exclusive worldwide license for its lead compounds, Elpida (elsulfavirine) and VM1500A, which are in phase 3 and commercial stages of development. Additionally, the company has created proprietary drug candidates, including VM2500 and VM3500 LAI formulations, along with various combinations involving cell, vaccine, and antibody therapies aimed at treating, preventing, and potentially curing HIV and chronic HBV infections. Viriom is committed to advancing healthcare solutions for these serious viral diseases on a global scale.

TealTech MMO develop a way to avoid unnecessary travel, waiting and worry when you do not feel well. What if instead of coming to a doctor, a doctor will come to you? There are already doctors doing home calls, but still most of the primary care is provided in clinics, since medical equipment and laboratory are not portable. Digital era changes the game. With point-of-care diagnostics, secure cloud data-bases and telemedicine we can make doctor’s office portable. Miniaturization of diagnostic and laboratory devices along with telecommunication helps to avoid travel, waiting and exposure to other patient’s pathogens by replacing the unnecessary ER/Urgent care visits with a professional care in the comfort of patient’s home. Mobile Office Point-of-Care lab ensures hospital quality rapid blood, and urine testing 24/7 along with instrumental tests and on-line consultations’ by specialists. We enable family doctors to continuously serve their patients - after hours, during weekends and travel time. The key elements are: · Care in the comfort of patients’ home (nurse house call visits within 1.5 hour after a call) · Point-of-care diagnostics enabling results of lab and instrumental tests in minutes during the house call visit; · Providing a patient with tools to objectively monitor health parameters and communicate them to the doctor at any time; · Dramatic reduction of the paperwork for doctors and nurses allowing to spend more time with a patient; · Control the quality of care by peer reviews (second opinion) and patient evaluation of the services and results of the treatment; Service Traveling nurses visit patients at home, provide on-site diagnostics and communication with primary physicians and specialists to treat a wide spectrum of diseases. Nurses come equipped with hospital grade POC diagnostic instruments to provide quality care 24/7 and replace costly ER visits for non-life threatening conditions. Product The product consists of hardware and software. The hardware is a set of FDA-approved portable diagnostic devices including blood cell counter, blood chemistry, coagulation meter, urine analyzer, pathogen and biomarker detecting devices, ultrasound, ECG, vital signs monitor, digital stethoscope and multipurpose video camera. All devices are connected to the laptop and packed in the convenient lightweight case that fits in the trunk of the car and can be easily delivered to the patient’s bed. The software enables automatic secure transfer of the test and lab results from devices into the patient records and further to any EHR. The friendly interface tailored to primary care needs reduces the amount of time physicians spend on paperwork and patient evaluation by automating diagnosis, prescription creation, and progress notes. Unlike other EMRs the system works in on-line and off-line mode and could be applied at any patient site independent of Internet accessibility. Mobile Medical Office platform connects patients with healthcare providers, enabling scheduling of house call visits similar to scheduling Uber taxi rides as well as secured video chat with a doctor or a team of doctors.

Chromis Therapeutics Inc. is a biopharmaceutical company based in San Diego, California, dedicated to developing curative treatments for chronic hepatitis B virus (HBV) infection. The company utilizes an advanced proprietary drug design and discovery platform to create innovative antiviral therapies. Its lead candidates include a cccDNA inhibitor, viral entry inhibitor, and core assembly inhibitor, all of which are currently in preclinical development. Among these, CHR101, the cccDNA inhibitor, shows significant promise as it has the potential to eradicate HBV and provide a more effective cure for chronically infected patients compared to existing treatments. Chromis Therapeutics aims to advance these novel therapeutics to improve patient outcomes while minimizing side effects.

Viriom Inc. is a biotechnology company based in Khimki, Russia, established in 2009. It specializes in developing innovative and affordable medicines for life-threatening infections, particularly HIV and Hepatitis B virus (HBV). Viriom holds an exclusive worldwide license for its lead compounds, Elpida (elsulfavirine) and VM1500A, which are in phase 3 and commercial stages of development. Additionally, the company has created proprietary drug candidates, including VM2500 and VM3500 LAI formulations, along with various combinations involving cell, vaccine, and antibody therapies aimed at treating, preventing, and potentially curing HIV and chronic HBV infections. Viriom is committed to advancing healthcare solutions for these serious viral diseases on a global scale.

Chromis Therapeutics Inc. is a biopharmaceutical company based in San Diego, California, dedicated to developing curative treatments for chronic hepatitis B virus (HBV) infection. The company utilizes an advanced proprietary drug design and discovery platform to create innovative antiviral therapies. Its lead candidates include a cccDNA inhibitor, viral entry inhibitor, and core assembly inhibitor, all of which are currently in preclinical development. Among these, CHR101, the cccDNA inhibitor, shows significant promise as it has the potential to eradicate HBV and provide a more effective cure for chronically infected patients compared to existing treatments. Chromis Therapeutics aims to advance these novel therapeutics to improve patient outcomes while minimizing side effects.

Viriom Inc. is a biotechnology company based in Khimki, Russia, established in 2009. It specializes in developing innovative and affordable medicines for life-threatening infections, particularly HIV and Hepatitis B virus (HBV). Viriom holds an exclusive worldwide license for its lead compounds, Elpida (elsulfavirine) and VM1500A, which are in phase 3 and commercial stages of development. Additionally, the company has created proprietary drug candidates, including VM2500 and VM3500 LAI formulations, along with various combinations involving cell, vaccine, and antibody therapies aimed at treating, preventing, and potentially curing HIV and chronic HBV infections. Viriom is committed to advancing healthcare solutions for these serious viral diseases on a global scale.

Leap Therapeutics is a clinical-stage biopharmaceutical company focused on developing targeted and immuno-oncology therapeutics. Its primary focus is to advance translational-stage molecules in cell signaling and immuno-oncology areas.

Avelas Biosciences is focused on advancing cancer surgery through innovative intraoperative imaging technology. The company has developed a proprietary platform that utilizes activatable cell-penetrating peptides to provide real-time diagnosis of metastatic nodes during surgical procedures. This technology enables oncologic surgeons to create a luminous map of the surgical area, improving their ability to identify and remove cancerous tissue effectively. By enhancing surgical precision, Avelas Biosciences aims to reduce the need for repeat surgeries and ultimately improve patient outcomes, establishing a new standard of care in oncological surgery.

T23 Biopharmaceutical, based in San Diego, California, specializes in developing pre-clinical and clinical stage biopharmaceutical solutions. The company focuses on creating targeted immunotherapies to treat patients with cancer and autoimmune diseases. Its lead product, T101, is a conjugate of siglec ligand and nanosomal formulation currently in pre-clinical development.

Precision Repair Network is a specialized provider of wheelchair repair services, focusing on power wheelchair maintenance and component replacement. The company operates nationally across the contiguous 48 states, employing a network of highly-trained service engineers and technicians who deliver on-site support to clients. By addressing wheelchair safety and repair needs, Precision Repair Network aims to enhance mobility, independence, and overall quality of life for individuals who rely on power wheelchairs or scooters. The company's commitment to customer service ensures that clients receive timely and effective solutions tailored to their specific requirements.

Avelas Biosciences is focused on advancing cancer surgery through innovative intraoperative imaging technology. The company has developed a proprietary platform that utilizes activatable cell-penetrating peptides to provide real-time diagnosis of metastatic nodes during surgical procedures. This technology enables oncologic surgeons to create a luminous map of the surgical area, improving their ability to identify and remove cancerous tissue effectively. By enhancing surgical precision, Avelas Biosciences aims to reduce the need for repeat surgeries and ultimately improve patient outcomes, establishing a new standard of care in oncological surgery.

TeaRx Ltd. is a pharmaceutical company based in Moscow, Russian Federation, focused on developing innovative therapeutic drugs aimed at preventing thrombosis-related illnesses, including deep venous thrombosis (DVT) and pulmonary embolism (PE). The company specializes in a new class of anticoagulants known as blood coagulation factor Xa inhibitors, which utilize a thioredoxin molecule essential for treating various diseases and performing surgical procedures. By enabling medical institutions to prevent thromboembolism, TeaRx aims to enhance patient outcomes and save lives.

SatRx LLC is a biotechnology company established in 2010 and headquartered in Khimki, Russian Federation. The company specializes in the discovery, development, and commercialization of treatments for diabetes, obesity, cardiovascular diseases, and other metabolic disorders, as well as therapies related to transplantology, primarily in the CIS region. Operating as a subsidiary of ChemRar Ltd, SatRx focuses on both pharmaceutical development and pre-clinical development to advance its innovative biopharmaceutical offerings.

BioIntegrator, Ltd. is a biotechnology company based in the Russian Federation that specializes in the development and manufacturing of pharmaceutical products derived from recombinant proteins and other macromolecules. The company produces a variety of substances, including monoclonal antibodies and biological materials using E. coli and chemical synthesis. BioIntegrator focuses on the purification and formulation of these products, employing transfer technology in its manufacturing processes. As a subsidiary of ChemRar Ltd., BioIntegrator is committed to advancing biopharmaceutical innovations.

Tensha Therapeutics is a biotechnology company focused on developing small molecule bromodomain inhibitors, a novel class of epigenetic modulators designed to alter gene expression. The company's research is based on groundbreaking discoveries made by Dr. James Bradner at the Dana-Farber Cancer Institute, leading to the creation of first-in-class, potent BET bromodomain inhibitors. Tensha's primary therapeutic program targets the treatment of BRD4-NUT midline carcinoma, acute myeloid leukemia, multiple myeloma, and other serious conditions. By harnessing the potential of these innovative compounds, Tensha aims to advance cancer treatment and improve patient outcomes.

Avionco delivers services to the business, commercial, and private aviation sectors.

NewVac

Aviron Ltd engages in the research and development of specific antiviral agents against chronic Hepatitis C Virus (HCV) infection. The company has strategic alliances with CHEMRAR Hi-Tech Center, Chemical Diversity Research Institute, and DRUGS TECHNOLOGY, Ltd. Aviron Ltd was founded in 2010 and is based in Moscow, Russian Federation.

Avineuro Pharmaceuticals, Inc. is a biopharmaceutical company based in San Diego, California, focused on discovering and developing novel small molecules to address unmet medical needs in neurology and psychiatry. Founded in 2008, Avineuro combines modern medicinal chemistry with efficient pre-clinical and clinical development processes to expedite the transition of drug candidates to proof-of-concept. The company seeks to acquire promising lead compounds through strategic collaborations and partnerships, aiming to create innovative products and enhance the therapeutic potential of existing compounds. Avineuro's commitment to addressing significant medical challenges positions it as a key player in the field of neurological and psychiatric healthcare.

Afraxis, Inc. is a contract research organization based in San Diego, California, founded in 2007. The company specializes in preclinical efficacy evaluations, including in vivo and in vitro studies, neurotoxicity assessments, and structure-efficacy relationship-driven medicinal chemistry. Afraxis has developed enhanced spine profiling technology, which provides detailed insights into synaptic networks through high-resolution imaging and rapid morphometric analysis of individual neurons and synapses. Additionally, the company offers services in drug discovery and high-content analysis, encompassing live cell imaging and advanced statistical methods for data interpretation. Afraxis focuses on developing treatments for central nervous system disorders, including schizophrenia, Alzheimer's disease, Fragile X syndrome, and autism spectrum disorders, while also researching proprietary PAK inhibitors for these conditions.

Viriom Inc. is a biotechnology company based in Khimki, Russia, established in 2009. It specializes in developing innovative and affordable medicines for life-threatening infections, particularly HIV and Hepatitis B virus (HBV). Viriom holds an exclusive worldwide license for its lead compounds, Elpida (elsulfavirine) and VM1500A, which are in phase 3 and commercial stages of development. Additionally, the company has created proprietary drug candidates, including VM2500 and VM3500 LAI formulations, along with various combinations involving cell, vaccine, and antibody therapies aimed at treating, preventing, and potentially curing HIV and chronic HBV infections. Viriom is committed to advancing healthcare solutions for these serious viral diseases on a global scale.

AllaChem LLC, established in 2004 and headquartered in Hallandale Beach, Florida, specializes in drug discovery and development for treating infectious diseases, cancer, and CNS disorders. Its pipeline includes AV4025 (completed Phase 1a for chronic hepatitis C), AVR560 (in clinical development for HCV), AV5075C/AV5080 (preclinical oral drugs for influenza treatment), and ONC1-13B (preclinical compound targeting prostate and breast cancers). The company employs a rational approach combining modern medicinal chemistry with efficient preclinical and clinical studies to create drugs with improved pharmacokinetics, efficacy, and safety profiles.